Study Population Individuals aged 18 years were eligible on the basis of their having a pharmacy claim for an index drug (semaglutide or DPP4i) during the index date selection window (January 1, 2018 to October 10, 2020) and their having a confirmed T2D diagnosis, defined as 2 claims for International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) code on distinct days between January 1, 2017 and September 30, 2022, with 1 record during the baseline period
At Rheumatologist OnCall, were committed to staying at the forefront of emerging treatments
Mistake 8: losing track of the reconstitution date If you cannot remember when you reconstituted the vial, you cannot know if you are within the 28-day use window
In recent years, peptide-based weight-loss drugs, such as GLP-1R agonists and GLP-1R/GIPR dual receptor agonists, have gained widespread global use
do not massage